14 ?March 2024

BSF Enterprise PLC

("BSF" or the "Company")

BSF Investor Evening

BSF Enterprise would like to welcome current shareholders and interested investors to an Investor Evening organised by Shard Capital Partners LLP on Tuesday, 19 March 2024.

At the event, a presentation will be delivered by the management of BSF Enterprise, followed by a Q&A session.

Hospitality will be provided.

The event will take place at 1790 Bar, St Swithin's Lane, London from 17.30

To register your interest in attending, please use the following link: https://forms.gle/FEmtcZT4mAA1DzS99

********************************************

Notes to Editors

About BSF Enterprise PLC:

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas for testing to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality leather from its laboratory in Newcastle, transforming the leather industry towards an ethical and sustainable practice. 

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to develop a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale. 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.